OSCR
Oscar Health, Inc.
OSCR has the edge over XTNT overall, supported by stronger fundamentals and stronger modeled upside.
XTNT
Xtant Medical Holdings, Inc.
XTNT has slightly lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
XTNT Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Strong |
XTNT's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
XTNT PE Valuation
XTNT has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
XTNT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect XTNT's losses to shrink, with revenue growing.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over XTNT on earnings quality, reporting a profit while its opponent remains loss making.
XTNT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.08 | -$0.04 |
| Q1 2026 | $0.01 | +$0.10 |
| Q4 2025 | $0.03 | +$0.15 |
| Q3 2025 | $0.01 | +$0.13 |
| Q2 2025 | -$0.04 | -$0.03 |
| Q1 2025 | -$0.09 | -$0.09 |
| Q4 2024 | -$0.12 | -1300% |
| Q3 2024 | -$0.12 | -700% |
XTNT is still losing money, but far less than before: $0.08 per share over the past year, against $5.15 at its worst in late 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over XTNT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over XTNT on profitability, with a higher operating margin.
XTNT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $23M | -35% |
| Q1 2026 | $20.9M | -37% |
| Q4 2025 | $32.4M | +2.7% |
| Q3 2025 | $33.3M | +19% |
| Q2 2025 | $35.4M | +18% |
| Q1 2025 | $32.9M | +18% |
| Q4 2024 | $31.5M | +12% |
| Q3 2024 | $27.9M | +12% |
XTNT's revenue has slid since its 2025 peak: $23M last quarter, down 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -40% | -53 points |
| Q1 2026 | -14% | -17 points |
| Q4 2025 | -2.9% | +3 points |
| Q3 2025 | 7.6% | +21 points |
| Q2 2025 | 13% | +23 points |
| Q1 2025 | 3.2% | +16 points |
| Q4 2024 | -6% | +7.6 points |
| Q3 2024 | -14% | 0 points |
XTNT's operating margin was −40% last quarter, down 53 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over XTNT on cash generation, producing positive trailing cash flow while its opponent burns cash.
XTNT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$7.6M | -930% |
| Q1 2026 | -$2.3M | -2753% |
| Q4 2025 | $5M | +$5M |
| Q3 2025 | $4.2M | +$8M |
| Q2 2025 | $910K | +$6.6M |
| Q1 2025 | $87K | +$6.6M |
| Q4 2024 | -$7K | +$1.3M |
| Q3 2024 | -$3.8M | +$235K |
XTNT has burned cash in most quarters: −$696,000 over the past year, against −$3M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
XTNT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +200K shares |
| 1 year | -5.6% | -8.3M shares |
| 3 years | +29% | +31.4M shares |
| 5 years | +62% | +53.6M shares |
| Available history | +966% | +127M shares |
XTNT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
XTNT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 3.4x | Elevated |
| Q2 2021 | -4.0x | Net Cash |
| Q1 2021 | -0.9x | Net Cash |
| Q4 2020 | 10.9x | High |
| Q3 2020 | 66.6x | High |
XTNT has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
XTNT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 5.3 | Oversold |
XTNT's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
XTNT PE vs Healthcare Sector
| Metric | XTNT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
XTNT has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over XTNT on trend strength, trading above more of its moving averages.
XTNT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.31 | 9.7% below |
| 20 week MA | $0.35 | 20% below |
| 50 week MA | $0.49 | 43% below |
| 100 week MA | $0.54 | 48% below |
| 200 week MA | $0.69 | 59% below |
XTNT is in a downtrend: it's below all five of its weekly moving averages, and 59% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over XTNT on returns for 2026, with the stronger performance.
XTNT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.67 | $1.20 | -28% |
| 2021 | $1.20 | $0.66 | -45% |
| 2022 | $0.66 | $0.66 | 0% |
| 2023 | $0.66 | $1.13 | +71% |
| 2024 | $1.13 | $0.46 | -59% |
| 2025 | $0.46 | $0.78 | +70% |
| 2026 YTD | $0.78 | $0.28 | -64% |
XTNT has finished lower in four of the last six years. It's down 64% so far in 2026.